221 related articles for article (PubMed ID: 25723369)
1. The rise of biosimilars in cancer care.
Roe H
Br J Nurs; 2015 Feb 26-Mar 11; 24(4):S28-9. PubMed ID: 25723369
[No Abstract] [Full Text] [Related]
2. [Biosimilars - Potential, risks and open questions].
Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
[No Abstract] [Full Text] [Related]
3. How biosimilars will impact costs and care in oncology.
Lyman GH
Clin Adv Hematol Oncol; 2019 Oct; 17(10):544-547. PubMed ID: 31730579
[No Abstract] [Full Text] [Related]
4. Introduction and commentary: Paving the way for biosimilars in oncology.
Abraham J
Semin Oncol; 2013 Dec; 40 Suppl 1():S1-4. PubMed ID: 24267943
[No Abstract] [Full Text] [Related]
5. Pharmacovigilance and biosimilars: considerations, needs and challenges.
Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
Bennett CL; Sartor OA; Armitage JO; Kantarjian H
Lancet Oncol; 2017 Jan; 18(1):22-23. PubMed ID: 28049571
[No Abstract] [Full Text] [Related]
7. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
8. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
Cesarec A; Likić R
Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
[TBL] [Abstract][Full Text] [Related]
9. Empower physicians to fight financial toxicity with biosimilars.
Oubre K
Am J Manag Care; 2019 Dec; 25(12 Spec No.):SP374-SP375. PubMed ID: 31860250
[No Abstract] [Full Text] [Related]
10. [Biosimilars: assessment of efficacy, safety and cost].
Domínguez-Gil Hurlé A
Farm Hosp; 2010 Mar; 34 Suppl 1():25-8. PubMed ID: 20920855
[TBL] [Abstract][Full Text] [Related]
11. Friction in the Path to Use of Biosimilar Drugs.
Frank RG
N Engl J Med; 2018 Mar; 378(9):791-793. PubMed ID: 29490182
[No Abstract] [Full Text] [Related]
12. Biosimilars for insulin: a cost-saving alternative?
McCall C
Lancet; 2018 Aug; 392(10146):463-464. PubMed ID: 30129449
[No Abstract] [Full Text] [Related]
13. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
Grabowski HG; Guha R; Salgado M
Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
[TBL] [Abstract][Full Text] [Related]
14. The economic implications of biosimilars.
Singh SC; Bagnato KM
Am J Manag Care; 2015 Dec; 21(16 Suppl):s331-40. PubMed ID: 26788809
[TBL] [Abstract][Full Text] [Related]
15. FDA Biosimilar Action Plan: could improving pharmacovigilance of biologics improve patient and physician confidence in biosimilars?
Jordan JB; Christl L
Expert Opin Drug Saf; 2020 Mar; 19(3):229-232. PubMed ID: 32098520
[No Abstract] [Full Text] [Related]
16. Biosimilar drugs: Measures to promote their use.
Guiu Segura JM; Gilabert Perramon A
Med Clin (Barc); 2020 Feb; 154(4):148. PubMed ID: 30981435
[No Abstract] [Full Text] [Related]
17. Biosimilars for Management of Crohn Disease.
Nielsen OH; Ainsworth MA
Ann Intern Med; 2019 Jan; 170(2):129-130. PubMed ID: 30535358
[No Abstract] [Full Text] [Related]
18. A Conversation with Gary Lyman, MD: Biosimilars and the Search for the Cure To Cancer Treatment's Financial Toxicity.
Wehrwein P
Manag Care; 2019 Jan; 28(1):12-15. PubMed ID: 30883317
[TBL] [Abstract][Full Text] [Related]
19. Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings.
Patel D; Park KT
J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):134-136. PubMed ID: 28319603
[TBL] [Abstract][Full Text] [Related]
20. The changing landscape of biosimilars in rheumatology.
Dörner T; Strand V; Cornes P; Gonçalves J; Gulácsi L; Kay J; Kvien TK; Smolen J; Tanaka Y; Burmester GR
Ann Rheum Dis; 2016 Jun; 75(6):974-82. PubMed ID: 26964144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
